Methods of administering anti-fibrotic therapy
US-11925624-B2 · Mar 12, 2024 · US
Methods of administering anti-fibrotic therapy
US12310951B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12310951-B2 |
| Application number | US-202418440652-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 13, 2024 |
| Priority date | Nov 30, 2016 |
| Publication date | May 27, 2025 |
| Grant date | May 27, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure relates to methods of administering Compound I for treating fibrotic disorders, inflammatory disorders or autoimmune disorders.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of administering Compound I to treat a subject suffering from a fibrotic disorder said method comprising increasing the maximal plasma concentration (C max ) or the extent of absorption (AUC 0-t or AUC 0-∞ ) of Compound I wherein the C max or AUC of Compound I with food is increased compared to the C max or AUC of the same amount of Compound I administered without food.
Assignees
Inventors
Classifications
containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465) · CPC title
Drugs for immunological or allergic disorders · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
Immunomodulators · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12310951B2 cover?
- The present disclosure relates to methods of administering Compound I for treating fibrotic disorders, inflammatory disorders or autoimmune disorders.
- Who is the assignee on this patent?
- Genentech Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/437. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue May 27 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).